Klebsiella Pneumoniae is a gram-negative bacterium that is known for causing infection 2 in nosocomial settings. As reported by WHO, this bacterial pathogen is classified as an 3 urgent threat our most concern is that these bacterial pathogens acquired genetic traits 4 that make them resistant towards antibiotics. The last class of antibiotics; carbapenems 5 are not able to combat these bacterial pathogens allowing them to clonally expand their 6 antibiotic-resistant strain. Most antibiotics target the essential pathways of the bacteria 7 cell however these targets are no longer susceptible to the antibiotic. Hence in our study, 8 we focus on Klebsiella Pneumoniae bacterial strains that contain DNA Adenine 9 Methyltransferase domain which suggests a new potential site for a drug target. DNA 10 methylation is seen to regulate the attenuation of bacterial virulence. In this study, all 11 hypothetical proteins of Klebsiella Pneumoniae containing N6 DNA Adenine 12 Methyltransferase domain were analysed for a potential drug target. About 32 13 hypothetical proteins were retrieved from Uniprot. 19 proteins were selected through a 14 step-wise subtractive genomics approach like a selection of non-homologus proteins 15 against the human host, selection of bacterial proteins contains an essential gene, broad-16 spectrum analysis, druggability analysis, Non-homology analysis against gut 17 microbiota. Through drug target prioritization like sub-cellular analysis, drug property 18 analysis, anti-target non-homology analysis, virulence factor analysis and protein-19 protein interaction analysis one drug target protein (Uniprot ID: A0A2U0NNR3) was 20 prioritized. Identified drug target docked with potential inhibitors like are mahanine 21 (PubChem ID: 375151), curcumin (PubChem ID: 969516), EGCG (PubChem ID: 22 65064), nanaomycin A (PubChem ID: 40586), parthenolide (PubChem ID: 7251185), 23 quercetin (PubChem ID: 5280343) and trimethylaurintricarboxylic acid. Based on the 24 moelcular docking analysis, mahanine has the highest binding affinity. In order to 25 identify novel natural inhibitor based on mahanine fingerprint search is performed 26 against NPASS (Natural Product Activity and Species Source databases) and 27 Koenimbine was identified as a novel natural inhibitor based on virtual screening.
Introduction
The concerning emergence of this bacterial pathogen MDR has become a global 11 threat and this MDR and as mentioned by WHO (2012) . These bacterial pathogens 12 clonally expand acquiring genetical traits allowing them to develop resistant causing an 13 increase prevalence affecting the human population by suppressing the mortality and 14 morbidity rate. The current antibiotics are not able to combat this bacterial pathogen 15 allowing them to acquire mobile genetic traits that make them resistant towards the 16 antibiotics. Although, the carbapenems and colistin are identified as the 2 most potent 17 antibiotics however this bacteria producing resistant towards these antibiotics and 18 identified as Klebsiella Pneumoniae Carbapenems(KPCs) producing (Giordano et al. 19 2017). 20 DNA Adenine Methyltransferase(Dam) is seen as a promising drug target as it 21 involves in the epigenetics regulatory machinery that helps in sustaining the viability of 22 the bacterial pathogens and regulates the bacterial pathogenicity (Natasya, Ismail, and 23 Kumar 2019). Evidently, Dam is seen to regulate the modulation of that bacterial 24 pathogen making them a promising drug target for future drug discovery 25 (Giacomodonato et al. 2014 ). Hence, this study aims to identify novel antibiotic drug 26 targets by targeting the Dam for Klebsiella Pneumonia. 1 DrugBank is extensively used for a new drug target in silico computational aided 2 drug design (Hosen et al. 2015) . The database consists of the data with more 3 comprehensive information on the drug target and action of the drug. The drug data 4 included in the database are approved by the Food and Drug Administration (FDA). In 5 order to obtain the drugable protein, the hypothetical protein is subjected to BLASTp 6 with an E-value of 0.001. 7 2.5 Non-homology analysis against gut microbiota 8 Gut microbiota plays an important role in human gastrointestinal. The 9 homologous protein giving similarities to the human gut may interact and bind with the 10 gut flora proteins leading to adverse pharmacokinetic side effects in the host. Hence, a 11 homologous protein that is similar to the human gun is removed by using BLASTp with 12 an e-value of 0.0001 (Altschul, Stephen F Gish, Warren Miller, Webb Myers 1990 membrane location is cytoplasmic. Therefore, all of these aspects are first analyzed to 28 determine a good drug target.
Drugability analysis

29
To predict the length of amino acids, the ExPasy server is used to analyze the 1 length of amino acids, hydrophobicity and pI. (Bendtsen et al. 2004 As the protein identified is uncharacterized protein, it is therefore essential to are computed and the protein is saved as pdbqt file.
27
The grid box is set based on the predicted binding site with the configuration 28 values of the center grid box of x,y,z. The size of the dimension grid box is set to 30.0 29 Å. The binding affinity score is observed. are seen to be more favorable as drug targets as they contain an abundant enzyme 10 making it more feasible for a drug target. The cellular localization is predicted by using 11
Identification of novel inhibitor through molecular fingerprint search of the
PsortB. 9 protein is characterized by locating at the cytoplasmic membrane while 10 12 protein is unknown. membrane location is cytoplasmic.
20
One of the driven forces of a good drug target is having high hydrophobicity.
21
The balance of hydrophobicity of protein is significant to the folding of protein and A0A3P4UG76, and A0A2U0NNR3. Table 1 shows the screening of the 3 proteins. 
Identification of putative drug target 28
It is necessary to prognosticate the probable drug candidate to fail. Therefore, 29 the protein needs to first be identified as either an anti target or target protein. The anti 30 target protein is a protein receptor that when it binds to a drug, it will cause adverse 31 pharmacokinetics side effects. Here, all 3 proteins are not anti-target proteins.
Out of these 3 proteins, protein A0A2U0NNR3 is seen to have more desireable 1 drug property when analyzed by using chEMBL with 10 matches. Figure 4 greatly 2 summarizes the screening process to identify the potential drug target. Also, this protein 3 shows the highest pocket binding score of 0.82 when analyzed by using DogSiteScorer.
4
The protein then further studies for its metabolic pathway. Based on the metabolic 5 pathway analysis in the KEGG server, the protein is found to carries a unique pathway 6 of DNA mismatch repair. The gene ontology to describe the specific biological role of 7 the protein indicates that the protein carries a gene that functions as a site-specific of 8 DNA methyltransferase (adenine specific activity). The metabolic pathway and gene 9 ontology are summarized in Table 2 .
10
In order to understand the virulence mechanism, the protein is queried to 
Protein-protein interaction 18
Protein is not able to function alone, therefore the neighbouring protein is 19 identified. Based on Figure 5 , the interacting neighbouring protein helps to decipher the 20 interactome mechanism in bacteria protein. Neighboring protein scored greater than 0.7 21 are considered as high confidence interacting protein which can be seen in Figure 6 .
22
The significant protein identified is tryptophanyl t-RNA synthetase, ribulose phosphate Initially, the protein structure A0A2U0NNR3 is searched in Protein Data Bank.
27
The search resulted that the protein structure is not available. The protein sequence is 28 submitted to SWISS-MODEL for the construction of the protein structure. The modeled 29 structure is imposed based on the retrieved template from the SWISS-MODEL template 30 library of PDB ID: 4RTL. To ensure the structural quality of the model, the protein is 31 first evaluated. The evaluation is done by using PROCHECK, ERRAT, and PRoSA.
32
PROCHECK construct Ramachandran plot that gives 89.9% of residues in the favored 1 regions, 9.4% regions in the additional allowed regions and 0.4% for both residues in 2 generously and disallowed regions. According to Kumar (2015) , good quality of protein 3 structure should give an overall of residues in the favored and allowed regions of over 4 90%. Here, the model gives a total of 89.9% + 9.4% = 99.3%.
5
The Z-score value from ProSA is -7.49 that indicates that the model is by the X-6 ray crystallography method. ERRAT plot gives the overall factor quality score of 7 84.848 that gives an average quality score. The overall results can be referred to in 8 Figure 8 and based on the results, the protein model can be inferred for further study.
9
The ligands that are sourced from the literature review are first analyzed for any 10 violations of Lipinski Rules. Only ECGC is excluded as it gives 2 violations of Lipinski
11
Rules: N or O>10, NH or OH>5.
12
The inhibitors are docked and defined to which the predicted binding pocket by 13 using DogSiteScorer. Figure 7 shows the area in which the active region is identified.
14 The dimension grid is set to 30 Å. Based on the result tabulated in Table 4, Mahanine   15 gives the highest binding affinity score of -10.8 kcal/mol followed by Nanaomycin A Table 4 . .
28
The virtual screen result is tabulated in Figure 5 .All the ligands are seen to no 29 violate Lipinski Rules. The virtual screening is performed by using AutoDock. The 30 virtual screening resulted that Koenimbine and Claurailas B have the highest binding 31 affinity score of -5.97 kcal/mol. Koenimbine is also one of the carbazole alkaloids of the same plant species, can be explored as the novel antibiotics. Figure 9 shows the 1 binding of Koenimbine and Table 5 shows the ligand-binding score and drug-likeness 2 property.
3
ADMET test 4
The ADMET test was further evaluated for Koenimbine to understand the absorption, the human intestine is 93.479% which indicates a good absorption rate. It also results 10 in being a P-glycoprotein II inhibitor which is significant in imposing pharmacokinetics 11 effects.
12
In terms of distribution, koenimbine is seen to have slightly low distribution in the tissue 13 plasma as the volume of distribution is 0.654 L/kg. Based on the toxicity measured, the 14 T.pyriformis toxicity indicates that the compound is highly toxic against bacteria with 15 0.948 ug/L. The compound is also seen to be mutagenic against bacteria which indicates 16 that it can cause detrimental to the bacteria. The result is summarized in Table 6 . pneumonia based on subtractive genomics, based on drug property, pocket analysis, 20 pathway analysis, and structure analysis. Our proposed new computational pipeline 21 approach helps to find out the drug target in a rapid way. We have also discovered that 9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35 
